PK/PD of Caspofungin in Children Severe Infection

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · Jul 5, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the body processes the antifungal medication caspofungin in children with severe infections. The researchers want to understand how different health conditions, like liver problems or being on a special type of life support called ECMO, affect how caspofungin works in young patients. This is important because children’s bodies may react differently to medications, especially when they are very sick.

The trial is open to children aged 91 days to 6574 days who are already receiving caspofungin in a pediatric intensive care unit. To participate, families must provide informed consent, and children cannot be involved in other clinical trials at the same time. Participants will help researchers gather valuable information that could improve the treatment of serious fungal infections in children facing challenging health situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children receiving caspofungin in pediatric intensive care unit
• Exclusion Criteria:
• • No Informed Consent signed Participate in other clinical trials